{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:55:18Z","timestamp":1791197718011,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:00:00Z","timestamp":1643587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:00:00Z","timestamp":1643587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5R50CA211462"],"award-info":[{"award-number":["5R50CA211462"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50CA127297"],"award-info":[{"award-number":["P50CA127297"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50CA127297"],"award-info":[{"award-number":["P50CA127297"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008114","name":"University of Nebraska-Lincoln","doi-asserted-by":"publisher","award":["NRI2132270010"],"award-info":[{"award-number":["NRI2132270010"]}],"id":[{"id":"10.13039\/100008114","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008114","name":"University of Nebraska-Lincoln","doi-asserted-by":"publisher","award":["NRI2132270010"],"award-info":[{"award-number":["NRI2132270010"]}],"id":[{"id":"10.13039\/100008114","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010537","name":"Nebraska Department of Health and Human Services","doi-asserted-by":"publisher","award":["LB595 Cowan Recruitment (SY Kim)"],"award-info":[{"award-number":["LB595 Cowan Recruitment (SY Kim)"]}],"id":[{"id":"10.13039\/100010537","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pancreatic ductal adenocarcinoma (PDAC) patients display distinct phenotypes of cachexia development, with either adipose tissue loss preceding skeletal muscle wasting or loss of only adipose tissue. Activin A levels were measured in serum and analyzed in tumor specimens of both a cohort of Stage IV PDAC patients and the genetically engineered KPC mouse model. Our data revealed that serum activin A levels were significantly elevated in Stage IV PDAC patients in comparison to age-matched non-cancer patients. Little is known about the role of activin A in adipose tissue wasting in the setting of PDAC cancer cachexia. We established a correlation between elevated activin A and remodeling of visceral adipose tissue. Atrophy and fibrosis of visceral adipose tissue was examined in omental adipose tissue of Stage IV PDAC patients and gonadal adipose tissue of an orthotopic mouse model of PDAC. Remarkably, white visceral adipose tissue from both PDAC patients and mice exhibited decreased adipocyte diameter and increased fibrotic deposition. Strikingly, expression of thermogenic marker UCP1 in visceral adipose tissues of PDAC patients and mice remained unchanged. Thus, we propose that activin A signaling could be relevant to the acceleration of visceral adipose tissue wasting in PDAC-associated cachexia.\n<\/jats:p>","DOI":"10.1038\/s41598-022-05660-7","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T11:18:07Z","timestamp":1643627887000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Visceral adipose tissue remodeling in pancreatic ductal adenocarcinoma cachexia: the role of activin A signaling"],"prefix":"10.1038","volume":"12","author":[{"given":"Pauline C.","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikyoung","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-Yeong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Eldani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C.","family":"Caffrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Grandgenett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly A.","family":"O\u2019Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surendra K.","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandramohan","family":"Kattamuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Hollingsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas B.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soonkyu","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So-Youn","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,31]]},"reference":[{"key":"5660_CR1","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/nrc3829","volume":"14","author":"JM Argil\u00e9s","year":"2014","unstructured":"Argil\u00e9s, J. M., Busquets, S., Stemmler, B. & L\u00f3pez-Soriano, F. J. Cancer cachexia: Understanding the molecular basis. Nat. Rev. Cancer 14, 754\u2013762. https:\/\/doi.org\/10.1038\/nrc3829 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"5660_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3322\/caac.21364","volume":"67","author":"MK Barton","year":"2017","unstructured":"Barton, M. K. Cancer cachexia awareness, diagnosis, and treatment are lacking among oncology providers. CA A Cancer J. Clin. 67, 91\u201392. https:\/\/doi.org\/10.3322\/caac.21364 (2017).","journal-title":"CA A Cancer J. Clin."},{"key":"5660_CR3","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/nrc927","volume":"2","author":"MJ Tisdale","year":"2002","unstructured":"Tisdale, M. J. Cachexia in cancer patients. Nat. Rev. Cancer 2, 862\u2013871. https:\/\/doi.org\/10.1038\/nrc927 (2002).","journal-title":"Nat. Rev. Cancer"},{"key":"5660_CR4","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/s1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon, K. et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 12, 489\u2013495. https:\/\/doi.org\/10.1016\/s1470-2045(10)70218-7 (2011).","journal-title":"Lancet Oncol."},{"key":"5660_CR5","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.Can-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib, L. et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Can. Res. 74, 2913\u20132921. https:\/\/doi.org\/10.1158\/0008-5472.Can-14-0155 (2014).","journal-title":"Can. Res."},{"key":"5660_CR6","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1097\/mpa.0000000000001124","volume":"47","author":"SE Henderson","year":"2018","unstructured":"Henderson, S. E., Makhijani, N. & Mace, T. A. Pancreatic cancer-induced cachexia and relevant mouse models. Pancreas 47, 937\u2013945. https:\/\/doi.org\/10.1097\/mpa.0000000000001124 (2018).","journal-title":"Pancreas"},{"key":"5660_CR7","doi-asserted-by":"publisher","first-page":"788","DOI":"10.3892\/mco.2013.131","volume":"1","author":"F Tas","year":"2013","unstructured":"Tas, F., Sen, F., Keskin, S., Kilic, L. & Yildiz, I. Prognostic factors in metastatic pancreatic cancer: Older patients are associated with reduced overall survival. Mol. Clin. Oncol. 1, 788\u2013792. https:\/\/doi.org\/10.3892\/mco.2013.131 (2013).","journal-title":"Mol. Clin. Oncol."},{"key":"5660_CR8","doi-asserted-by":"publisher","first-page":"17105","DOI":"10.1038\/nrdp.2017.105","volume":"4","author":"VE Baracos","year":"2018","unstructured":"Baracos, V. E., Martin, L., Korc, M., Guttridge, D. C. & Fearon, K. C. H. Cancer-associated cachexia. Nat. Rev. Dis. Prim. 4, 17105. https:\/\/doi.org\/10.1038\/nrdp.2017.105 (2018).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"5660_CR9","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/bjc.1997.17","volume":"75","author":"SJ Wigmore","year":"1997","unstructured":"Wigmore, S. J., Plester, C. E., Richardson, R. A. & Fearon, K. C. H. Changes in nutritional status associated with unresectable pancreatic cancer. Br. J. Cancer 75, 106\u2013109. https:\/\/doi.org\/10.1038\/bjc.1997.17 (1997).","journal-title":"Br. J. Cancer"},{"key":"5660_CR10","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1002\/jcsm.12307","volume":"9","author":"JK Kays","year":"2018","unstructured":"Kays, J. K. et al. Three cachexia phenotypes and the impact of fat-only loss on survival in FOLFIRINOX therapy for pancreatic cancer. J. Cachexia. Sarcopenia Muscle 9, 673\u2013684. https:\/\/doi.org\/10.1002\/jcsm.12307 (2018).","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"5660_CR11","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1053\/j.gastro.2019.01.039","volume":"156","author":"RP Sah","year":"2019","unstructured":"Sah, R. P. et al. Phases of metabolic and soft tissue changes in months preceding a diagnosis of pancreatic ductal adenocarcinoma. Gastroenterology 156, 1742\u20131752. https:\/\/doi.org\/10.1053\/j.gastro.2019.01.039 (2019).","journal-title":"Gastroenterology"},{"key":"5660_CR12","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature13528","volume":"513","author":"S Kir","year":"2014","unstructured":"Kir, S. et al. Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature 513, 100\u2013104. https:\/\/doi.org\/10.1038\/nature13528 (2014).","journal-title":"Nature"},{"key":"5660_CR13","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.cmet.2012.01.019","volume":"15","author":"H Ohno","year":"2012","unstructured":"Ohno, H., Shinoda, K., Spiegelman, B. M. & Kajimura, S. PPAR\u03b3 agonists Induce a white-to-brown fat conversion through stabilization of PRDM16 protein. Cell Metabol. 15, 395\u2013404. https:\/\/doi.org\/10.1016\/j.cmet.2012.01.019 (2012).","journal-title":"Cell Metabol."},{"key":"5660_CR14","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.cmet.2014.06.011","volume":"20","author":"M Petruzzelli","year":"2014","unstructured":"Petruzzelli, M. et al. A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab. 20, 433\u2013447. https:\/\/doi.org\/10.1016\/j.cmet.2014.06.011 (2014).","journal-title":"Cell Metab."},{"key":"5660_CR15","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1155\/2015\/182872","volume":"182872\u2013182872","author":"JM Argil\u00e9s","year":"2015","unstructured":"Argil\u00e9s, J. M., Stemmler, B., L\u00f3pez-Soriano, F. J. & Busquets, S. Nonmuscle tissues contribution to cancer cachexia. Mediators Inflamm. 182872\u2013182872, 2015. https:\/\/doi.org\/10.1155\/2015\/182872 (2015).","journal-title":"Mediators Inflamm."},{"key":"5660_CR16","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1152\/physrev.00002.2018","volume":"99","author":"E Bloise","year":"2019","unstructured":"Bloise, E. et al. Activin A in mammalian physiology. Physiol. Rev. 99, 739\u2013780. https:\/\/doi.org\/10.1152\/physrev.00002.2018 (2019).","journal-title":"Physiol. Rev."},{"key":"5660_CR17","doi-asserted-by":"publisher","first-page":"821","DOI":"10.3390\/biomedicines9070821","volume":"9","author":"W Qiu","year":"2021","unstructured":"Qiu, W., Kuo, C.-Y., Tian, Y. & Su, G. H. Dual roles of the activin signaling pathway in pancreatic cancer. Biomedicines 9, 821 (2021).","journal-title":"Biomedicines"},{"key":"5660_CR18","doi-asserted-by":"publisher","first-page":"7986","DOI":"10.1038\/s41598-021-87213-y","volume":"11","author":"G Mancinelli","year":"2021","unstructured":"Mancinelli, G. et al. Role of stromal activin A in human pancreatic cancer and metastasis in mice. Sci. Rep. 11, 7986. https:\/\/doi.org\/10.1038\/s41598-021-87213-y (2021).","journal-title":"Sci. Rep."},{"key":"5660_CR19","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1158\/0008-5472.Can-19-3763","volume":"80","author":"Y Zhao","year":"2020","unstructured":"Zhao, Y. et al. Oncogene-induced senescence limits the progression of pancreatic neoplasia through production of activin A. Can. Res. 80, 3359\u20133371. https:\/\/doi.org\/10.1158\/0008-5472.Can-19-3763 (2020).","journal-title":"Can. Res."},{"key":"5660_CR20","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/jcsm.12209","volume":"8","author":"A Loumaye","year":"2017","unstructured":"Loumaye, A. et al. Circulating activin a predicts survival in cancer patients. J. Cachexia. Sarcopenia Muscle 8, 768\u2013777. https:\/\/doi.org\/10.1002\/jcsm.12209 (2017).","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"5660_CR21","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1096\/fj.13-245894","volume":"28","author":"JL Chen","year":"2014","unstructured":"Chen, J. L. et al. Elevated expression of activins promotes muscle wasting and cachexia. FASEB J. 28, 1711\u20131723. https:\/\/doi.org\/10.1096\/fj.13-245894 (2014).","journal-title":"FASEB J."},{"key":"5660_CR22","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.3390\/cancers12123787","volume":"12","author":"A Narasimhan","year":"2020","unstructured":"Narasimhan, A. et al. Identification of potential serum protein biomarkers and pathways for pancreatic cancer cachexia using an aptamer-based discovery platform. Cancers 12, 3787 (2020).","journal-title":"Cancers"},{"key":"5660_CR23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12944-018-0657-0","volume":"17","author":"J Han","year":"2018","unstructured":"Han, J., Meng, Q., Shen, L. & Wu, G. Interleukin-6 induces fat loss in cancer cachexia by promoting white adipose tissue lipolysis and browning. Lipids Health Dis. 17, 14\u201314. https:\/\/doi.org\/10.1186\/s12944-018-0657-0 (2018).","journal-title":"Lipids Health Dis."},{"key":"5660_CR24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/jcsm.12037","volume":"7","author":"ML Batista","year":"2016","unstructured":"Batista, M. L. et al. Cachexia-associated adipose tissue morphological rearrangement in gastrointestinal cancer patients. J. Cachexia. Sarcopenia Muscle 7, 37\u201347. https:\/\/doi.org\/10.1002\/jcsm.12037 (2016).","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"5660_CR25","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s12885-017-3178-8","volume":"17","author":"MJ Alves","year":"2017","unstructured":"Alves, M. J. et al. Adipose tissue fibrosis in human cancer cachexia: the role of TGF\u03b2 pathway. BMC Cancer 17, 190. https:\/\/doi.org\/10.1186\/s12885-017-3178-8 (2017).","journal-title":"BMC Cancer"},{"key":"5660_CR26","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.cyto.2012.10.023","volume":"61","author":"ML Batista","year":"2013","unstructured":"Batista, M. L. et al. Adipose tissue-derived factors as potential biomarkers in cachectic cancer patients. Cytokine 61, 532\u2013539. https:\/\/doi.org\/10.1016\/j.cyto.2012.10.023 (2013).","journal-title":"Cytokine"},{"key":"5660_CR27","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1017\/S0007114512001067","volume":"109","author":"KMD Sebastiano","year":"2013","unstructured":"Sebastiano, K. M. D. et al. Accelerated muscle and adipose tissue loss may predict survival in pancreatic cancer patients: The relationship with diabetes and anaemia. Br. J. Nutr. 109, 302\u2013312. https:\/\/doi.org\/10.1017\/S0007114512001067 (2013).","journal-title":"Br. J. Nutr."},{"key":"5660_CR28","doi-asserted-by":"publisher","first-page":"14.39.11","DOI":"10.1002\/cpph.2","volume":"73","author":"JW Lee","year":"2016","unstructured":"Lee, J. W., Komar, C. A., Bengsch, F., Graham, K. & Beatty, G. L. Genetically engineered mouse models of pancreatic cancer: The KPC model (LSL-Kras(G12D\/+); LSL-Trp53(R172H\/+); Pdx-1-Cre), its variants, and their application in immuno-oncology drug discovery. Curr. Protocols Pharmacol. 73, 14.39.11-14.39.20. https:\/\/doi.org\/10.1002\/cpph.2 (2016).","journal-title":"Curr. Protocols Pharmacol."},{"key":"5660_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080580","volume":"8","author":"MP Torres","year":"2013","unstructured":"Torres, M. P. et al. Novel pancreatic cancer cell lines derived from genetically engineered mouse models of spontaneous pancreatic adenocarcinoma: Applications in diagnosis and therapy. PLoS ONE 8, e80580. https:\/\/doi.org\/10.1371\/journal.pone.0080580 (2013).","journal-title":"PLoS ONE"},{"key":"5660_CR30","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/BF00133561","volume":"10","author":"S Taniguchi","year":"1992","unstructured":"Taniguchi, S., Iwamura, T. & Katsuki, T. Correlation between spontaneous metastatic potential and type I collagenolytic activity in a human pancreatic cancer cell line (SUIT-2) and sublines. Clin. Exp. Metas. 10, 259\u2013266. https:\/\/doi.org\/10.1007\/BF00133561 (1992).","journal-title":"Clin. Exp. Metas."},{"key":"5660_CR31","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/labinvest.3700298","volume":"85","author":"KM Lee","year":"2005","unstructured":"Lee, K. M., Yasuda, H., Hollingsworth, M. A. & Ouellette, M. M. Notch2-positive progenitors with the intrinsic ability to give rise to pancreatic ductal cells. Lab. Invest. 85, 1003\u20131012. https:\/\/doi.org\/10.1038\/labinvest.3700298 (2005).","journal-title":"Lab. Invest."},{"key":"5660_CR32","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41366-018-0148-4","volume":"43","author":"M-S Nguyen-Tu","year":"2019","unstructured":"Nguyen-Tu, M.-S. et al. Inflammation-linked adaptations in dermal microvascular reactivity accompany the development of obesity and type 2 diabetes. Int. J. Obes. 43, 556\u2013566. https:\/\/doi.org\/10.1038\/s41366-018-0148-4 (2019).","journal-title":"Int. J. Obes."},{"key":"5660_CR33","doi-asserted-by":"publisher","first-page":"11239","DOI":"10.1038\/s41598-019-47519-4","volume":"9","author":"L Roa-Pe\u00f1a","year":"2019","unstructured":"Roa-Pe\u00f1a, L. et al. Keratin 17 identifies the most lethal molecular subtype of pancreatic cancer. Sci. Rep. 9, 11239. https:\/\/doi.org\/10.1038\/s41598-019-47519-4 (2019).","journal-title":"Sci. Rep."},{"key":"5660_CR34","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/00000478-200105000-00003","volume":"25","author":"RH Hruban","year":"2001","unstructured":"Hruban, R. H. et al. Pancreatic intraepithelial neoplasia: A new nomenclature and classification system for pancreatic duct lesions. Am. J. Surg. Pathol. 25, 579\u2013586 (2001).","journal-title":"Am. J. Surg. Pathol."},{"key":"5660_CR35","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41586-018-0235-7","volume":"558","author":"LV Danai","year":"2018","unstructured":"Danai, L. V. et al. Altered exocrine function can drive adipose wasting in early pancreatic cancer. Nature 558, 600\u2013604. https:\/\/doi.org\/10.1038\/s41586-018-0235-7 (2018).","journal-title":"Nature"},{"key":"5660_CR36","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/jcsm.12461","volume":"10","author":"X Zhong","year":"2019","unstructured":"Zhong, X. et al. The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy. J. Cachexia. Sarcopenia Muscle 10, 1083\u20131101. https:\/\/doi.org\/10.1002\/jcsm.12461 (2019).","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"5660_CR37","doi-asserted-by":"publisher","first-page":"8817","DOI":"10.1073\/pnas.91.19.8817","volume":"91","author":"MM Matzuk","year":"1994","unstructured":"Matzuk, M. M. et al. Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice. Proc. Natl. Acad. Sci. 91, 8817\u20138821. https:\/\/doi.org\/10.1073\/pnas.91.19.8817 (1994).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"5660_CR38","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1093\/molehr\/gam055","volume":"13","author":"Q Li","year":"2007","unstructured":"Li, Q. et al. Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein. Mol. Hum. Reprod. 13, 675\u2013683. https:\/\/doi.org\/10.1093\/molehr\/gam055 (2007).","journal-title":"Mol. Hum. Reprod."},{"key":"5660_CR39","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1677\/joe.1.05978","volume":"184","author":"YL Bao","year":"2005","unstructured":"Bao, Y. L. et al. Synergistic activity of activin A and basic fibroblast growth factor on tyrosine hydroxylase expression through Smad3 and ERK1\/ERK2 MAPK signaling pathways. J. Endocrinol. 184, 493. https:\/\/doi.org\/10.1677\/joe.1.05978 (2005).","journal-title":"J. Endocrinol."},{"key":"5660_CR40","doi-asserted-by":"publisher","first-page":"4351","DOI":"10.1210\/en.2006-0444","volume":"147","author":"C de Guise","year":"2006","unstructured":"de Guise, C. et al. Activin inhibits the human pit-1 gene promoter through the p38 kinase pathway in a smad-independent manner. Endocrinology 147, 4351\u20134362. https:\/\/doi.org\/10.1210\/en.2006-0444 (2006).","journal-title":"Endocrinology"},{"key":"5660_CR41","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1128\/mcb.25.1.60-65.2005","volume":"25","author":"L Zhang","year":"2005","unstructured":"Zhang, L. et al. MEKK1 transduces activin signals in keratinocytes to induce actin stress fiber formation and migration. Mol. Cell. Biol. 25, 60\u201365. https:\/\/doi.org\/10.1128\/mcb.25.1.60-65.2005 (2005).","journal-title":"Mol. Cell. Biol."},{"key":"5660_CR42","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.canlet.2020.07.025","volume":"491","author":"SE Mulder","year":"2020","unstructured":"Mulder, S. E. et al. JNK signaling contributes to skeletal muscle wasting and protein turnover in pancreatic cancer cachexia. Cancer Lett. 491, 70\u201377. https:\/\/doi.org\/10.1016\/j.canlet.2020.07.025 (2020).","journal-title":"Cancer Lett."},{"key":"5660_CR43","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.devcel.2018.05.026","volume":"45","author":"P Parajuli","year":"2018","unstructured":"Parajuli, P. et al. Twist1 activation in muscle progenitor cells causes muscle loss akin to cancer cachexia. Dev. Cell 45, 712-725.e716. https:\/\/doi.org\/10.1016\/j.devcel.2018.05.026 (2018).","journal-title":"Dev. Cell"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-05660-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-05660-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-05660-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T22:29:33Z","timestamp":1669328973000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-05660-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,31]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["5660"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-05660-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,31]]},"assertion":[{"value":"19 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1659"}}